SCHEMBL5368722

SCHEMBL5368722

COc1ccc(CN2CCN=C(c3ccccc3)c3ccccc32)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 1/20 0.47
NPSR1 Q6W5P4 3/20 0.43
GAA P10253 2/20 0.43
HTT P42858 2/20 0.43
GPR55 Q9Y2T6 1/20 0.43
ALDH1A1 P00352 2/20 0.43
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
CYP11B1 P15538 1/20 0.43
CYP11B2 P19099 1/20 0.43
NR1I2 O75469 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
HTR2C P28335 1/20 0.42
ADRA1A P35348 1/20 0.42
PTGS2 P35354 1/20 0.42
OPRK1 P41145 1/20 0.42
CHRNA4 P43681 1/20 0.42
SLC6A3 Q01959 1/20 0.42
PDE4D Q08499 1/20 0.42
MEN1 O00255 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2928292 0.81 OPRK1 (0.51) GAAALDH1A1NR1I2ADORA3HTR2C
SCHEMBL18398199 0.78 SIRT2 (0.47) SIGMAR1CYP11B1CYP11B2SMN1; SMN2SIRT2
SCHEMBL29381926 0.77 NPSR1 (0.72) NPSR1GAAHTTGPR55TSHR
SCHEMBL8276025 0.77 NPSR1 (0.72) NPSR1GAAHTTGPR55TSHR
SCHEMBL28295461 0.73 NR1I2 (0.50) NPSR1GAAHTTGPR55NR1I2
SCHEMBL29244907 0.73 ADRA1A (0.41) NPSR1HTTALDH1A1TSHRNR1I2
SCHEMBL29244913 0.72 ALDH1A1 (0.41) SIGMAR1GAAHTTALDH1A1TSHR
SCHEMBL11684214 0.71 HDAC3 (0.46) NPSR1GAAHTTGPR55ALDH1A1
SCHEMBL2478548 0.70 OPRK1 (0.69) NPSR1GAAHTTGPR55NR1I2
SCHEMBL27387296 0.70 HDAC3 (0.50) NPSR1GAAHTTGPR55ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238685-B2 Benzo-fused heterocycles as endothelin antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2007-07-03 US disclosed
US-20050124605-A1 Novel benzo-fused heterocycles as endothelin antagonisits ACTELION PHARMACEUTICALS LTD. 2005-06-09 US disclosed
WO-2003013545-A1 NOVEL BENZO-FUSED HETEROCYCLES AS ENDOTHELIN ANTAGONISITS ACTELION PHARMACEUTICALS LTD (CH) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124605-A1 Novel benzo-fused heterocycles as endothelin antagonisits EDNRA, EDNRB, ECE1 SIGMAR1 488/4885NPSR1 30/4885GAA 2736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.